Mingfeng Yu completed his PhD in organic chemistry at the University of Sydney under the supervision of Professors Matthew H. Todd and Peter J. Rutledge in 2013. His PhD research entailed the design, synthesis and evaluation of novel scorpionand metal-cyclam complexes appended with biologically-active motifs. He was appointed as a Research Fellow (Medicinal Chemistry) at the University of South Australia upon completion of his PhD, and was promoted to a Senior Research Fellow in 2020. Under the guidance of Professor Shudong Wang, he is currently involved in the discovery and development of patentable, highly potent and selective, and orally active enzyme inhibitors for targeted cancer therapy.